Pocket ObGyn – Uterine Fibroids

Pocket ObGyn – Uterine Fibroids 
See Abbreviations

Definition
  • Benign smooth muscle tumors, originating from myometrial tissue (leiomyoma).
  • Uterine fibroids can be classified based on their anatomical

Epidemiology (Obstet Gynecol Clin N Am 2011;38:703)

  • By 50 yo, fibroids are found in ~70% of whites & >80% of Indication for 30–40% of hysterectomies. Risks: >40 yo, black, FHx, nulliparity, obesity.

Figure 5.1 Fibroid location & nomenclature

Pedunculated serosal

Submucosal

 

 

 

Intramural                                           Subserosal

 

 

Pedunculated

submucosal                       Cervical

 

Pathology
  • Gross: Pearly, round, well Size & location vary. Relatively avascular but surrounded by rich vasculature system ® signif bleeding.
  • Histology: Smooth muscle cells aggregated in
  • Degenerating leiomyoma types: Hyaline (65%), myxomatous (15%), calcific (10%, mainly older women), cystic (4%, hylanized areas ® liquefaction), fatty (rare), carneous (red) necrosis (esp pregnant pts, acute d/t outgrowing bld supply ® acute musc infarction ® sev pain & local peritoneal irritation).
  • Leiomyomas do not transform into leiomyosarcoma. Likely represents a de novo neoplasm & is NOT a result of malig transformation of a benign
Pathophysiology
  • Fibroids are estrogen- (& progesterone-) sensitive Fibroids create ­ estrogen environment ® ­ growth & size maint. ­ estrogen conditions (obesity, early menarche) ® ­ fibroid risk.
Clinical Manifestations
  • Mostly Sx depend on size, location, & number. In general, the larger the fibroid, the larger the chance of sx.
  • Vaginal bleeding = most common symptom; usually presents as
  • Other sx: Pelvic pain & pres, urinary frequency, incontinence, constip, infertility
  • Evid sugg that myomas are the primary cause of infertility in a small # of Myomas that distort the uterine cavity & larger intramural myomas may have adverse effects on fertility (Fertil Steril 2008;90:S125).
Physical Exam & Diagnostic Studies
  • Findings: Uterine enlargement, irreg uterine
  • Must r/o other causes of abn Postmenopausal bleeding w/ fibroids should be evaluated the same way as women w/o fibroids.
  • Imaging:

US: Defines pelvic anatomy & effective in locating fibroids.

SIS: Allows eval of uterine cavity, particularly if infertility or menorrhagia is a concern. Good for submucosal type.

MRI: Very accurate.Very expensive. Not practical depending on the clinical setting.

Hysteroscopy: Gold std for submucosal fibroid.

Treatment & Medications
  • Observation: Asx fibroids do not require intervention, no matter their
  • Medical mgmt (Obstet Gynecol Clin N Am 2011;38:703): Should be tailored to alleviating Cost & s/e of rx may limit long-term use.

NSAIDs: No data to support use as sole agent for therapy. Good for dysmenor- rhea based on role of PGs as pain mediators.

OC: 1st line. Combined OCs may control bleeding & pain, but progestin-only OCs w/ mixed results.

Levonorgestrel IUD: Beneficial for menorrhagia. ­ rate expulsion & vaginal spotting.

GnRH agonist (Leuprolide 3.75–11.25 mg/m IM): Reversible amenorrhea in most, & 35–65% ¯ in size w/i 3 mo. Most useful in women w/ large fibroids.

Induces menopause sx + ¯ bone density. Consider add-back therapy for pro- longed use (>6 mo) or symptomatic pts. Use preop ® ¯ uterine size before Surg.

Aromatase inhibs: Block ovarian & periph estrogen production ® ¯ estradiol level after 1 d of rx. ¯ s/e compared to GnRH w/ rapid results. Little data.

Antiprogestins (Mifepristone 5 or 10 mg/d ¥ 6 mo): 26–74% ¯ in uterine vol & ¯ recurrent growth after cessation. S/e: Endometrial hyperplasia (dose- dependent) & transient ­ in transaminase (monit LFTs).

•   Nonsurgical mgmt:

UAE: IR injects PVA spheres into bilateral uterine artery ® ¯ bld flow ® ischemia & necrosis ® ¯ size & sx. Postembolization syn may require hospitalization postop for pain control. Successful pregnancies occur after UAE, but long-term data lim- ited.

US ablation under magnetic resonant guidance:
  • Surgical Mgmt:

Hysteroscopic myomectomy: 1st line for symptomatic submucosal fibroids.

Myomectomy: Option for those desiring fertility or decline hysterectomy. Goal to remove visible & accessible fibroids, & reconstruct uterus.Via laparotomy or laparoscopy. Fibroids may recur. When myomectomy invades endometrial cavity (complete wall resxn) consider CS deliv @ 37–38 w gest (Obstet Gynecol 2011;118:323).

Hysterectomy: Definitive surgical rx. Satisfaction rate >90%.

 

See Abbreviations